O
NVCR icon

Ossiam’s NovoCure NVCR Stock Holding History

Ossiam’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-4,102
Closed -$170K – 709
2023
Q2 		$170K Buy
4,102
+2,551
+164% +$158K ﹤0.01% 621
2023
Q1 		$93.3K Sell
1,551
-290
-16% -$23.2K ﹤0.01% 617
2022
Q4 		$135K Hold
1,841
– – ﹤0.01% 524
2022
Q3 		$140K Buy
+1,841
New +$144K ﹤0.01% 497

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Ossiam's NVCR Position: Q3 2023 in Review

Ossiam sold out of NovoCure (NVCR) in Q3 2023, closing a stake of 4,102 shares — an estimated $170K sold.

Ossiam first reported a position in NVCR in Q3 2022 and held it in 4 quarters. The position peaked at $170K in Q2 2023. 226 funds tracked by Wall St. Rank hold NVCR as of Q3 2023.

  • Ossiam reported no remaining NovoCure position as of Q3 2023 after selling out during the quarter.
  • Ossiam sold 4,102 NovoCure shares in Q3 2023, an estimated $170K.
  • Ossiam first reported a position in NovoCure in Q3 2022 and held it in 4 quarters.
  • Ossiam's NovoCure position peaked at $170K in Q2 2023.
  • 226 funds tracked by Wall St. Rank held NovoCure as of Q3 2023.

Based on Ossiam's 13F filing for Q3 2023, filed 14 Nov 2023.